Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 280

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 280
---
 and 2022, the Company
recorded an expense of $1,951 and $205 for the revaluation of such 2020 Notes, within financial expense, net in the statements of comprehensive
loss.

<div align='center'>F-30</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES (Cont.) |

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   | December 31, 
         2023 |   |     |   | December 31, 
         2022 |   |
|:-----------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |          900 |   |     | $ |          900 |   |
| Discount rate    |     |   |         30.0 | % |     |   |         30.0 | % |
| Term (years)     |     |   |         0.25 |   |     |   |          0.5 |   |
| Fair value       |     | $ |        7,405 |   |     | $ |        5,454 |   |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the fair value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM. As of December 31, 2023, a 5.0% decrease
in discount rate would increase the fair value of the 2020 Notes to $7,479; a 5.0% increase in discount rate would decrease the fair value
of the 2020 Notes to $7,334.

| b. | In September 2021, the Company entered into various Convertible Loan Agreements (the “2021 CLA”) for a total consideration of $835 thousand (the “2021 Notes”). Unless previously converted or repaid, the 2021 Notes shall mature and become payable 18 months following September 2021 (the “Maturity Date”). |

The